$3.09
-2.8%Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
SRTS โข NASDAQ
| Sensus Healthcare, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||
27.5M | 41.8M | 24.4M | 44.5M | 27M | 9.6M | 27.3M | 26.4M | 20.6M | 14.8M | 10.3M | 5.8M | 10.5M | |
GROSS PROFIT | |||||||||||||
(15.6M) | (17.4M) | (10.3M) | (14.9M) | (10.1M) | (4.3M) | (9.7M) | (9.5M) | (6.8M) | (5M) | (3.7M) | (2.1M) | (3.6M) | |
11.9M | 24.4M | 14.1M | 29.6M | 17M | 5.2M | 17.6M | 16.9M | 13.8M | 9.8M | 6.6M | 3.8M | 6.9M | |
OPERATING INCOME | |||||||||||||
(22.2M) | (16.3M) | (14.4M) | (14.8M) | (12.9M) | (13.5M) | (19.5M) | (18.9M) | (17.5M) | (10.2M) | (6.8M) | (7.4M) | (6.8M) | |
(14.4M) | (12.1M) | (10.8M) | (11.3M) | (9.4M) | (9.3M) | (13.1M) | (12.7M) | (12M) | (8.4M) | (5.3M) | (5.9M) | (5.4M) | |
(7.8M) | (4.2M) | (3.7M) | (3.5M) | (3.4M) | (4.2M) | (6.4M) | (6.3M) | (5.5M) | (1.8M) | (1.5M) | (1.6M) | (1.3M) | |
-10.3M | 8.1M | -382K | 14.8M | 4.1M | -8.2M | -2M | -2M | -3.7M | -363.1K | -221.3K | -3.7M | 126.8K | |
PRE-TAX INCOME | |||||||||||||
(0.0) | (0.0) | (0.0) | (2K) | (1K) | (14K) | (0.0) | (156.7K) | (68.9K) | (21.9K) | (17.8K) | (20K) | (20.5K) | |
683K | 932K | 992K | 380K | 1K | 52K | 268.3K | -17.4K | 6.9K | 16.7K | -16K | -19.2K | -19.2K | |
683K | 932K | 1M | 13.2M | -1K | 1.4M | 268.3K | -17.4K | 6.9K | 16.7K | -16K | -19.2K | -19.2K | |
-9.6M | 9M | 652K | 28M | 4.1M | -6.8M | -1.7M | -2M | -3.7M | -346.4K | -237.3K | -3.7M | 107.6K | |
NET INCOME | |||||||||||||
-1.9M | (2.4M) | (167K) | (3.7M) | (0.0) | (0.0) | -545.7K | (0.0) | (0.0) | (0.0) | (1.8K) | (820.0) | (0.0) | |
-7.7M | 6.6M | 485K | 24.2M | 4.1M | -6.8M | -1.7M | -2M | -3.7M | -346.4K | -237.3K | -3.7M | 107.6K |
SRTS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | May 29, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | May 29, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 20, 2026 | January 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Continue your SRTS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.